Treatment of sepsis by plasma endotoxin removal: Hemoperfusion using a polymyxin-B immobilized column

Innate Immunity

Volumn 4, Issue 4, 1997, Pages 293-300

  Kodama, M ^a   Tani, T ^a   Hanasawa, K ^a   Hirata, K ^b   Hirasawa, H ^c   Oda, S ^c   Otsuka, T ^d   Yamamoto, Y ^d   Kanesaka, S ^e   Takahashi, Y ^e   Maekawa, K ^f   Wakabayashi, Y ^g   Tamakuma, S ^h   Sugimoto, T ⁱ  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

ⁱ OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958170935     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/096805199700400407     Document Type: Article

References (30)

1. Ryan J.L.Microbial factors in pathogenesis: lipopolysaccharides. In: Root R.K., Sande M.Y. eds. Septic Shock. New York: Churchill Livingstone, 1985; 1-12.
2. Wolff S.M.Monoclonal antibodies and the treatment of Gram-negative bacteremia and shock. N Engl J Med1991; 324: 486-488.
3. Ruokonen E., Takala J., Kari A., Alhava E.Septic shock and multiple organ failure. Crit Care Med1991; 19: 1146-1151.
4. Remick D.G., Kunkel S.L.Toxic effects of cytokines in vivo. Lab Invest1989; 60: 317-319.
5. Schlievert P.M.Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic endotoxin type C. Infect Immum1981; 36: 123-128.
6. Abraham E., Wunderink R., Silverman H.et al.Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA1995; 273: 934-941.
7. Pribble J., Fisher C., Opal S.Human recombinant interleukin-1 receptor antagonist (IL-1Ra) increases survival time in patients with sepsis syndrome and end organ dysfunction [Abstract]. Crit Care Med1994; 22: A192.
8. Starnes H.F., Pearce M.K., Tewari A., Yim J.H., Zou Jian-Chao, Abrams J.S. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-challenge in mice. J Immunol1990; 145: 4185-4191.
9. Ziegler E.J., Fisher C.J., Sprung C.L.et al.Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med1991; 324: 429-436.
10. Greenman R.L., Schein R.H., Martin M.A.et al.A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA1991; 255: 1097-1102.
11. Newton B.A. A fluorescent derivative of polymyxin: its preparation and use in studying the site of the antibiotic. J Gen Microbiol1955; 12: 226-236.
12. Duff G.W., Waisman D.M., Atkins E.Removal of endotoxin by a polymyxin B affinity column. Clin Res1982; 30: 565A.
13. Niwa M., Umeda M., Ohashi K.A novel endotoxin binding substance, polymyxin sepharose. Jpn J Med Sci Biol1982; 35: 114-115.
14. Kodama Hanasawa K., Tani T.New therapeutic method against septic shock - removal of endotoxin using extracorporeal circulation. In: Friedman H., Klein T.W, Nakano M., Nowotny A. eds. Endotoxin. New York: Plenum, 1989; 953-965.
15. Hanasawa K., Tani T., Kodama M.New approach to endotoxin and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet1989; 168: 323-331.
16. Cheadle W.G., Hanasawa K., Gallinaro R.N., Nimmanwudipong T., Kodama M., Polk Jr H.C.Endotoxin filtration and immune stimulation improve survival from Gram-negative sepsis. Surgery1991; 110: 785-792.
17. Bendee S., Bertok L.Elimination of endotoxin from the blood by extracorporeal activated charcoal hemoperfusion in experimental canine endotoxin shock. Circ Shock1986; 19: 239-244.
18. Hanasawa K., Tani T., Oka T.et al.Comparison among three adsorbents in detoxifying endotoxin. Jpn J Artif Organs1986; 15: 1414-1418.
19. Bone R.C., Fisher C.J., Clemmer T.P.et al.Sepsis syndrome: a valid clinical entity. Crit Care Med1989; 17: 389-393.
20. Goris J.A., Boekhorst T.P.A., Nuytinck J.K.S.et al.Multiple-organ failure. Arch Surg1985; 120: 1109-1115.
21. Stevens L.E.Gauging the severity of surgical sepsis. Arch Surg1983; 118: 1190-1192.
22. Fujii S., Hitomi Y.New synthetic inhibitors of Clr, Cl esterase, thrombin, plasmin, kallikrein, and trypsin. Biochim Biophys Acta1981; 661: 342-345.
23. Endo Y., Tani T., Oka T.et al.Application of protease inhibitor to hemoperfusion and plasma exchange as a regional anticoagulant. Trans Am Soc Artif Intern Organs1985; 31: 429-432.
24. Inada K., Endo S., Takahashi K.et al.Establishment of a new perchloric acid treatment method to allow determination of the total endotoxin content in human plasma by the Limulus test and clinical application. Microbiol Immunol1991; 35: 303-314.
25. Obayashi T., Tamura H., Tanaka S.et al.A new chromogenic endotoxin-specific assay using recombined Limulus coagulation enzymes and its clinical applications. Clin Chem Acta1985; 149: 55-65.
26. Bone R.C., Balk R.A., Cerra F.B.et al.American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med1992; 20: 864-874.
27. Suffredini A.F., Fromm R.E., Parker M.M.et al.The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med1989; 321: 280-287.
28. Parrillo J.E., Parker M.M., Natanson C.et al.Septic shock in humans. Ann Intern Med1990; 113: 227-242.
29. Tracey K.J., Beutler B., Lowry S.F.et al.Shock and tissue injury induced by recombinant human cachectin. Science1986; 234: 470-474.
30. Rothstein J.L., Schreiber H.Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci USA1988; 85: 607-611.